GLPwatch
[Effect of byetta on renal osmoregulatory function in patients with diabetes mellitus].
Eksp Klin Farmakol · 2014
Last updated 2026-05-28In a study of people with type 2 diabetes, the drug Byetta (exenatide) at a 5 microgram dose improved the kidneys' ability to remove excess water in those with well-controlled blood sugar (HbA1c around 6.0%), but had no effect in those with poorly controlled blood sugar (HbA1c around 8.8%). Specifically, water excretion increased by about 1.4 mL/min in the well-controlled group, while the poorly controlled group showed no meaningful change.
AI summary of the abstract below.
| Journal | Eksp Klin Farmakol, 2014 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
The renal osmoregulatory function was studied in patients with type 2 diabetes mellitus (DM). The renal response to water loading (0.7% b.w.) and simultaneous exenatide (byetta) injection (5 microg) exhibited variation and was dependent on the degree of hyperglycemia. Effective solute-free water excretion was observed in patients with well-controlled DM (HbAlc 6.0 +/- 0.1%), in which CH20 changed from -0.67 +/- 0.2 mL/min to 0.72 +/- 0.2 mL/min. This reaction was absent in patients with poorly controlled DM (HbAlc 8.8 +/- 0.6%) and the process of solute-free water reabsorption prevailed: -CH20 = -1.06 +/- 0.1 mL/min in control period vs. -0.99 +/- 0.1 mL/min after treatment. Thus, byetta increases the efficiency of osmoregulation and accelerates the excretion of excess water in patients with compensated carbohydrate metabolism.
Verbatim abstract via PubMed 24800522 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.